{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:42:21Z","timestamp":1783788141498,"version":"3.55.0"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Post-traumatic headache (PTH) is a common and debilitating consequence of traumatic brain injury (TBI), often resembling migraine and tension-type headaches. Despite its prevalence, the optimal treatment for PTH remains unclear, with current strategies largely extrapolated from other headache disorders. This review evaluates the use of onabotulinumtoxin A (ONA) and anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in the treatment of PTH. A comprehensive literature search was conducted on PubMed, including studies published up to September 2024, focusing on the efficacy, safety, and mechanisms of onabotulinumtoxin A and anti-CGRP mAbs in PTH. Both clinical trials and observational studies were reviewed. ONA, widely recognized for its efficacy in chronic migraine, has shown limited benefits in PTH with only one trial involving abobotulinumtoxin A in a cohort of 40 subjects. A phase 2 trial with fremanezumab, an anti-CGRP monoclonal antibody, failed to demonstrate significant efficacy in PTH, raising questions about the utility of targeting CGRP in this condition. ONA may offer advantages over anti-CGRP mAbs, not only in terms of its broader mechanism of action but also in cost-effectiveness and higher patient adherence. Both ONA and anti-CGRP mAbs are potential options for the management of PTH, but the current evidence is insufficient to establish clear guidelines. The negative results from the fremanezumab trial suggest that CGRP inhibition may not be sufficient for treating PTH, whereas onabotulinumtoxin A\u2019s ability to target multiple pain pathways may make it a more promising candidate.<\/jats:p>","DOI":"10.3390\/toxins16100427","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T06:27:31Z","timestamp":1727850451000},"page":"427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Onabotulinumtoxin A for the Treatment of Post-Traumatic Headache: Is It Better than Anti-CGRP Antibodies?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-6135","authenticated-orcid":false,"given":"Dilara","family":"Onan","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Yozgat Bozok University, Yozgat 66800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"School of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1089\/neu.2011.1914","article-title":"Natural history of headache after traumatic brain injury","volume":"28","author":"Hoffman","year":"2011","journal-title":"J. Neurotrauma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41582-019-0243-8","article-title":"Post-traumatic headache: Epidemiology and pathophysiological insights","volume":"15","author":"Ashina","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_5","unstructured":"Tessler, J., and Horn, L.J. (2024). Posttraumatic Headache, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1526-4610.2010.01700.x","article-title":"Headaches after concussion in US soldiers returning from Iraq or Afghanistan","volume":"50","author":"Theeler","year":"2010","journal-title":"Headache"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mavroudis, I., Ciobica, A., Luca, A.C., and Balmus, I.M. (2023). Post-Traumatic Headache: A Review of Prevalence, Clinical Features, Risk Factors, and Treatment Strategies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134233"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s42399-023-01431-1","article-title":"Posttraumatic Stress Disorder Complicated by Traumatic Brain Injury: A Narrative Review","volume":"5","author":"Aita","year":"2023","journal-title":"SN Compr. Clin. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0006-8993(91)90755-K","article-title":"Dynamic changes in local cerebral glucose utilization following cerebral conclusion in rats: Evidence of a hyper- and subsequent hypometabolic state","volume":"561","author":"Yoshino","year":"1991","journal-title":"Brain Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1161\/01.STR.0000043073.69602.09","article-title":"Spreading and synchronous depressions of cortical activity in acutely injured human brain","volume":"33","author":"Strong","year":"2002","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tins.2016.03.002","article-title":"Traumatic Axonal Injury: Mechanisms and Translational Opportunities","volume":"39","author":"Hill","year":"2016","journal-title":"Trends Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0333102416681571","article-title":"Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache","volume":"38","author":"Bree","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11910-022-01175-w","article-title":"Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling","volume":"22","author":"Ashina","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11916-017-0624-x","article-title":"Behavioral Treatments for Post-Traumatic Headache","volume":"21","author":"Fraser","year":"2017","journal-title":"Curr. Pain. Headache Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s10194-019-1051-7","article-title":"Acute and preventive pharmacological treatment of post-traumatic headache: A systematic review","volume":"20","author":"Larsen","year":"2019","journal-title":"J. Headache Pain."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data","volume":"42","author":"Ducros","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","article-title":"Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins","volume":"43","author":"Dolly","year":"2003","journal-title":"Headache"},{"key":"ref_18","first-page":"S36","article-title":"Botulinum Toxin in Migraine Treatment","volume":"50","year":"2013","journal-title":"Noro Psikiyatr. Ars."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1533-2500.2008.00202.x","article-title":"Evidence for the use of botulinum toxin in the chronic pain setting\u2014A review of the literature","volume":"8","author":"Jeynes","year":"2008","journal-title":"Pain Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e32372","DOI":"10.1097\/MD.0000000000032372","article-title":"Botox (onabotulinumtoxinA) mechanism of action","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/03331024221099841","article-title":"Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache","volume":"42","author":"Navratilova","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e236433","DOI":"10.1136\/bcr-2020-236433","article-title":"Shot in the dark: Three patients successfully treated with onabotulinumtoxin A injections for relief of post-traumatic chronic headaches and dystonia induced by gunshot wounds","volume":"13","author":"Ferguson","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5114\/ninp.2012.32109","article-title":"Botulinum toxin in the treatment of post-traumatic headache\u2014Case study","volume":"46","year":"2012","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/head.12495","article-title":"Onabotulinum toxin A for the treatment of headache in service members with a history of mild traumatic brain injury: A cohort study","volume":"55","author":"Yerry","year":"2015","journal-title":"Headache"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/milmed\/usaa391","article-title":"Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study","volume":"186","author":"Zirovich","year":"2021","journal-title":"Mil. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: Physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1526-4610.2012.02160.x","article-title":"Nociceptive neuropeptide increases and periorbital allodynia in a model of traumatic brain injury","volume":"52","author":"Elliott","year":"2012","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1089\/neu.2015.4087","article-title":"Trigeminal pain molecules, allodynia, and photosensitivity are pharmacologically and genetically modulated in a model of traumatic brain injury","volume":"33","author":"Daiutolo","year":"2016","journal-title":"J. Neurotrauma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-017-0726-1","article-title":"Frequent mild head injury promotes trigeminal sensitivity concomitant with microglial proliferation, astrocytosis, and increased neuropeptide levels in the trigeminal pain system","volume":"18","author":"Tyburski","year":"2017","journal-title":"J. Headache Pain."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1177\/0333102419877662","article-title":"CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice","volume":"39","author":"Navratilova","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/ana.25915","article-title":"Hypersensitivity to calcitonin gene-related peptide in post-traumatic headache","volume":"88","author":"Ashina","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s10194-022-01499-5","article-title":"CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury","volume":"23","author":"Ashina","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s10194-020-01136-z","article-title":"Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: An open-label study","volume":"21","author":"Ashina","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_35","first-page":"5","article-title":"Treatment of Persistent Posttraumatic Headache with the Anti-CGRP Receptor Antibody Erenumab: A Case Report","volume":"169","author":"Papenhoff","year":"2023","journal-title":"SN Compr. Clin. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/02699052.2020.1807052","article-title":"Use of CGRP receptor blocker erenumab in the management of post-traumatic headache: A case series of 5 women","volume":"34","author":"VanderEnde","year":"2020","journal-title":"Brain Inj."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.96.15_supplement.1588","article-title":"A phase 2 study of fremanezumab as a treatment for posttraumatic headache in adult patients (1588)","volume":"96","author":"Spierings","year":"2021","journal-title":"Neurology"},{"key":"ref_38","unstructured":"(2024, September 30). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03347188."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.4103\/1673-5374.238619","article-title":"Relationship of calcitonin gene-related peptide with disease progression and prognosis of patients with severe traumatic brain injury","volume":"13","author":"Chen","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1007\/s00415-024-12181-y","article-title":"Serum calcitonin gene-related peptide in patients with persistent post-concussion symptoms, including headache: A cohort study","volume":"271","author":"Eggertsen","year":"2024","journal-title":"J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/0333102420941115","article-title":"Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine","volume":"23","author":"Khanal","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_43","first-page":"1119","article-title":"Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies","volume":"29","author":"Schwedt","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s10194-023-01636-8","article-title":"Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: A retrospective cohort study","volume":"24","author":"Charleston","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e16062","DOI":"10.1111\/ene.16062","article-title":"Comparative retention and effectiveness of migraine preventive treatments: A nationwide registry-based cohort study","volume":"31","author":"Borkenhagen","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-024-01762-x","article-title":"Effects of PDE-3 inhibition in persistent post-traumatic headache: Evidence of cAMP-dependent signaling","volume":"25","author":"Christensen","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-024-01808-0","article-title":"Hypersensitivity to BKCa channel opening in persistent post-traumatic headache","volume":"25","author":"Christensen","year":"2024","journal-title":"J. Headache Pain."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10194-022-01425-9","article-title":"Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor","volume":"23","author":"Juhler","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nurt.2009.10.018","article-title":"Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury","volume":"7","author":"Vink","year":"2010","journal-title":"Neurotherapeutics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/brain\/awad367","article-title":"Hypersensitivity to PACAP-38 in post-traumatic headache: A randomized clinical trial","volume":"147","author":"Christensen","year":"2024","journal-title":"Brain"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/10\/427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:17Z","timestamp":1760112557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/10\/427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["toxins16100427"],"URL":"https:\/\/doi.org\/10.3390\/toxins16100427","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}